B10 Cells Are Associated With Clinical Prognosis During Adult Symptomatic Acute HBV Infection.
B10
acute
cytokine
hepatitis B
interleukin-10
prognosis
regulatory B cell
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
28
03
2022
accepted:
17
05
2022
entrez:
30
6
2022
pubmed:
1
7
2022
medline:
2
7
2022
Statut:
epublish
Résumé
There are few reports about the role of B10 cells in acute hepatitis B (AHB) infection. In this study, based on 48 acute hepatitis B infected patients, we analysis the correlation of B10 cells with HBV clinical prognosis. The results showed that B10 was positively correlated with HBsAg and HBeAg and inversely correlated with anti-HBs. The level of B10 in one week before HBsAg clearance was significantly lower than 2 weeks prior to HBsAg clearance and after 1-2 weeks of HBsAg clearance. B10 cell frequency displayed no correlation with HBV DNA; however, it showed significant temporal synchronization with hepatic inflammatory markers such as ALT. B10 level also associated with hospitalization time. These results indicated that B10 is closely related to the clinical prognosis of acute HBV infection.
Identifiants
pubmed: 35769476
doi: 10.3389/fimmu.2022.906650
pmc: PMC9234142
doi:
Substances chimiques
Hepatitis B Surface Antigens
0
Hepatitis B e Antigens
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
906650Informations de copyright
Copyright © 2022 Liu, Du, Lu, Ma, Jing, Ben, Chen and Zhang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Lancet. 2012 Dec 15;380(9859):2095-128
pubmed: 23245604
J Dermatol Sci. 2019 Jan;93(1):2-7
pubmed: 30514664
Front Immunol. 2020 Aug 18;11:1571
pubmed: 32973738
Medicine (Baltimore). 2017 Feb;96(7):e6088
pubmed: 28207518
J Clin Invest. 2018 Oct 1;128(10):4588-4603
pubmed: 30091725
Front Immunol. 2020 Jul 28;11:1632
pubmed: 32849556
Nat Rev Rheumatol. 2014 Aug;10(8):452-3
pubmed: 24934192
Front Immunol. 2018 May 03;9:961
pubmed: 29774031
Science. 1999 Apr 30;284(5415):825-9
pubmed: 10221919
J Clin Invest. 2018 Oct 1;128(10):4573-4587
pubmed: 30084841
Hepatology. 2011 Jan;53(1):73-85
pubmed: 21254163
Cell Mol Immunol. 2018 Jun;15(6):645-648
pubmed: 29225341
Immunity. 2002 Feb;16(2):219-30
pubmed: 11869683
Gastroenterology. 2009 Oct;137(4):1289-300
pubmed: 19591831
J Clin Invest. 1996 Apr 1;97(7):1655-65
pubmed: 8601631
J Hepatol. 2011 Jul;55(1):53-60
pubmed: 21145853
Blood. 2011 Jan 13;117(2):530-41
pubmed: 20962324
Nat Rev Rheumatol. 2018 May;14(5):248
pubmed: 29540841
Int Immunol. 2000 May;12(5):597-605
pubmed: 10784605
Blood. 2013 Apr 18;121(16):3274-83
pubmed: 23422748
Front Immunol. 2021 Apr 12;12:653198
pubmed: 33912178
Lancet. 2018 Nov 24;392(10161):2313-2324
pubmed: 30496122
Semin Immunol. 2019 Aug;44:101335
pubmed: 31734129
JCI Insight. 2021 Apr 8;6(7):
pubmed: 33729999
Int Immunopharmacol. 2019 Feb;67:281-286
pubmed: 30572252
J Immunol. 2015 Feb 15;194(4):1395-401
pubmed: 25663677
Dig Dis Sci. 2015 May;60(5):1308-14
pubmed: 25260658
J Immunol. 2012 Oct 15;189(8):3925-35
pubmed: 22972930
Clin Sci (Lond). 2016 Jun 1;130(11):907-19
pubmed: 26980345
J Immunol. 1990 Nov 15;145(10):3442-9
pubmed: 2230128
J Hepatol. 2020 Jan;72(1):34-44
pubmed: 31348999
Mucosal Immunol. 2022 Feb;15(2):268-278
pubmed: 35013572
Nat Immunol. 2018 Apr;19(4):407-419
pubmed: 29483597